Cotransplant of donor-matched ILC2s reduces incidence of xeno-aGVHD following allo-HSCT. Sublethally irradiated NSG mice received human PBMCs, with 1 group receiving donor-matched cultured ILC2. (A) Diagram depicting isolation of PBMCs, and enrichment and expansion of HuILC2 from the same donor, and their use in a xenograft transplant model. (B) Kaplan-Meier plot of NSG recipient survival following transplant, 1 representative of 3 experiments using different donors is shown (n = 4 per experiment), log rank (Mantel-Cox) test. (C) Changes in weight and (D) clinical score of recipients from panel B, analyzed by 2-way analysis of variance, with Bonferroni correction for repeated measures of multiple comparisons, ∗∗∗P < .001. (E) Enzyme-linked immunosorbent assay quantification of human TNF in the serum of NSG recipients 28 days after transplant, represents 2 combined experiments, analyzed by 1-way analysis of variance with Tukey’s multiple comparison test, ∗P < .05. (F) To improve ILC2 survival, NSG mice were given IL-33 1 day prior to cell infusion. Flow cytometry plots of human ILC2 in the lung and liver of NSG mice 4 days after transplant, 1 example plot each, n = 6. BMT, bone marrow transplantation; ctrl, control; SSC, side scatter; w/, with.